Category: Press Release

SANTA CLARA, California, March 11, 2026 — Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company’s expanding capabilities across Canada and the United States. Agilent Advanced Therapeutics brings together the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in […]

Read More…

CHARLOTTETOWN, PEI and WORCESTER, MA – November 6, 2025 – BIOVECTRA, a part of Agilent Technologies Inc., and Revolution Biomanufacturing Inc. today announced a collaboration that grants BIOVECTRA access to Revolution Biomanufacturing’s proprietary platforms for optimizing untranslated regions (UTRs) and codon usage to enhance mRNA stability and translational efficiency. This partnership provides a fully integrated pathway […]

Read More…

CHARLOTTETOWN, Prince Edward Island – BIOVECTRA, a part of Agilent Technologies Inc., is a leading North American CDMO specializing in biologics, mRNA therapeutics, and complex chemistry, proudly announces it is the recipient of the 2025 Outsourced Pharma CDMO Leadership Award in the category of biologics. The award recognizes BIOVECTRA’s performance in key areas such as […]

Read More…

  Pharmaceutical customers will benefit from a broader set of specialized CDMO capabilities SANTA CLARA, California, September 20, 2024 – Agilent Technologies Inc. (NYSE: A) today announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules […]

Read More…

CHARLOTTETOWN, Prince Edward Island and SANTA CLARA, California – July 22, 2024 BIOVECTRA Inc. and Agilent Technologies, Inc. (NYSE: A) today announced the signing of an agreement for Agilent to acquire BIOVECTRA, a Canadian-based Contract Development and Manufacturing Organization, from H.I.G. Capital for $925 million. The acquisition provides the ability to expand the range of […]

Read More…

CHARLOTTETOWN, PRINCE EDWARD ISLAND, November 17th, 2023 –  Today BIOVECTRA celebrates the completion of its $90 million plus biologics expansion at the company’s new state-of-the-art Biomanufacturing Centre with project partners the Government of Canada and Government of Prince Edward Island. “This expansion places BIOVECTRA at the forefront of supporting the next generation of treatments for today’s […]

Read More…

CHARLOTTETOWN, Prince Edward Island and VANCOUVER, British Columbia, October 5, 2023 – BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service agreement under which BIOVECTRA will accept, on a non-exclusive basis, Acuitas’ best-in-class LNP technology platform for manufacturing mRNA-based therapeutics. “We are thrilled about this partnership with Acuitas […]

Read More…

  Charlottetown, P.E.I. (January 18, 2023) – BIOVECTRA is pleased to announce that Normand Blais was appointed as Senior Director, Development & Innovation, Biologics.  Reporting to the Chief Science Officer, Mr. Blais will be responsible for the strategic direction shaping BIOVECTRA’s pDNA & mRNA vaccine process science program. Mr. Blais is accomplished in early-candidate vaccine […]

Read More…

  Charlottetown, P.E.I. (November 22, 2022) – BIOVECTRA was selected as one of Canada’s Top 100 Employers for a second consecutive year and is considered amongst the country’s leading workplaces. BIOVECTRA is a fast growing, forward-thinking contract development, and manufacturing organization (CDMO) solving complex challenges to improve patient care for some of the world’s top […]

Read More…

  Charlottetown, CANADA, October 31, 2022 – BIOVECTRA is ready to accept projects at its manufacturing facility in Windsor, Nova Scotia, Canada, for its new, single-use biologics fermentation suite. Containing 100 L and 1,000 L single-use fermenters, this state-of-the-art process train enhances BIOVECTRA’s microbial fermentation overall network of capacity and allows BIOVECTRA to support even […]

Read More…